3,4-dihydroxyphenylacetic acid has been researched along with Akinetic-Rigid Variant of Huntington Disease in 15 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the BACHD model of Huntington's disease we demonstrate that the vector can be kept in a continuous ON-state for extended periods of time." | 1.48 | Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, S | 1 |
| Tereshchenko, J | 1 |
| Zimmer, V | 1 |
| Vachey, G | 1 |
| Pythoud, C | 1 |
| Rey, M | 1 |
| Liefhebber, J | 1 |
| Raina, A | 1 |
| Streit, F | 1 |
| Mazur, A | 1 |
| Bähr, M | 1 |
| Konstantinova, P | 1 |
| Déglon, N | 1 |
| Kügler, S | 1 |
| Puginier, E | 1 |
| Bharatiya, R | 1 |
| Chagraoui, A | 1 |
| Manem, J | 1 |
| Cho, YH | 1 |
| Garret, M | 1 |
| De Deurwaerdère, P | 1 |
| Renoir, T | 1 |
| Argyropoulos, A | 1 |
| Chevarin, C | 1 |
| Lanfumey, L | 1 |
| Hannan, AJ | 1 |
| Chen, S | 1 |
| Zhang, XJ | 1 |
| Xie, WJ | 1 |
| Qiu, HY | 1 |
| Liu, H | 1 |
| Le, WD | 1 |
| Kraft, JC | 1 |
| Osterhaus, GL | 1 |
| Ortiz, AN | 1 |
| Garris, PA | 1 |
| Johnson, MA | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 2 |
| Lastres-Becker, I | 1 |
| de Miguel, R | 1 |
| De Petrocellis, L | 1 |
| Makriyannis, A | 1 |
| Di Marzo, V | 1 |
| Fernández-Ruiz, J | 2 |
| de Lago, E | 1 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Ramos, JA | 1 |
| Walsh, FX | 1 |
| Bird, ED | 2 |
| Stevens, TJ | 1 |
| Melamed, E | 1 |
| Hefti, F | 1 |
| Nakazato, T | 1 |
| Akiyama, A | 1 |
| Andreassen, OA | 1 |
| Ferrante, RJ | 1 |
| Dedeoglu, A | 1 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Beal, MF | 1 |
| Rebec, GV | 1 |
| Barton, SJ | 1 |
| Ennis, MD | 1 |
| Garrett, MC | 1 |
| Soares-da-Silva, P | 1 |
| Isacson, O | 1 |
| Brundin, P | 1 |
| Gage, FH | 1 |
| Björklund, A | 1 |
15 other studies available for 3,4-dihydroxyphenylacetic acid and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression | 2018 |
Early neurochemical modifications of monoaminergic systems in the R6/1 mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Disease Models, Animal; Dopamine; D | 2019 |
Sexually dimorphic dopaminergic dysfunction in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitor | 2014 |
A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; DNA | 2015 |
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can | 2003 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Monoamine transmitters and their metabolites in the basal ganglia of Huntington's disease and control postmortem brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Basal Ganglia; Dopamine; Homovanillic Acid; Humans; Huntington Disea | 1982 |
Huntington chorea is not associated with hyperactivity of nigrostriatal dopaminergic neurons: studies in postmortem tissues and in rats with kainic acid lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Diseases; Corpus Striatum; Dopamine; Female; Homovani | 1982 |
In vivo electrochemical measurement of the long-lasting release of dopamine and serotonin induced by intrastriatal kainic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Circadian Rhythm; Corpus Striatum; Dopamine; | 1997 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Dysregulation of ascorbate release in the striatum of behaving mice expressing the Huntington's disease gene.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Ascorbic Acid; Behavior, Animal; Body Weight; Corpus Striat | 2002 |
Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Biogenic Amines; Brain; Dopamine; Female; Humans; Huntington | 1992 |
Neural grafting in a rat model of Huntington's disease: progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Choline O-Acetyltransferase; Corpus Striatum; Disease Model | 1985 |